The Termeer Foundation Announces Recipients of 2022 Henri Termeer Fellowship

BOSTON–(BUSINESS WIRE)–The Termeer Foundation, a nonprofit organization focused on connecting life science innovators and catalyzing the creation of new medicines, today announced that the Class of 2022 Henri Termeer Fellows has been named; the latest to receive this honor within the Fellowship program which began in 2018.

“This year’s group of Termeer Fellows represents a tremendous group of scientists and business leaders involved in novel work with strong potential impact on medical research, the business of biotech and ultimately those patients who live with a host of unmet medical needs”

The Henri Termeer Fellowship is awarded annually to emerging leaders within the life science industry who have shown initial promise as company founders, CEOs or heads of life science organizations and are dedicated to developing life-changing treatments for patients. Fellows receive membership in The Henri Termeer Network, a select group of emerging and established healthcare leaders who provide access to their collective and valuable industry experience to help all Termeer Fellows advance their businesses and scientific programs. Additional Fellowship benefits include mentorship, network building and professional development as well as peer-to-peer learning, and access to other events and initiatives sponsored by The Termeer Foundation.

“This year’s group of Termeer Fellows represents a tremendous group of scientists and business leaders involved in novel work with strong potential impact on medical research, the business of biotech and ultimately those patients who live with a host of unmet medical needs,” said Belinda Termeer, President of The Termeer Foundation. “It is the Foundation’s goal, through this recognition, to accelerate each Fellow’s visionary work and future developments, so that they may continue their innovative and insightful work across a diverse set of scientific platforms.”

The 2022 Fellows include: Alex Federation, Talus Bioscience, Inc., Daniel Fischer, Tevard Biosciences, Elizabeth Wood, JURA Bio, Inc., Xavier Duportet, Eligo Bioscience, Yael Weiss, Mahzi Therapeutics, Laura Kleiman, Reboot Rx, Lukas Lange, Probably Genetic, and Claudine van der Sande, Xinvento.

“Each year the selection of the Termeer Fellows becomes increasingly more competitive and challenging, and this year’s pool of outstanding applicants all have incredible promise of making a meaningful difference in the life science industry,” said Alan Walts, Co-Founder and Member of the Board of Directors, The Termeer Foundation. “The depth and range of each applicant’s background demonstrates the need for novel biomedical research and underscores the potential value for improving the health for patients.”

More on the Class of 2022 Fellows can be found here.

 

About The Termeer Foundation

Building on the bold legacy of Henri Termeer, who pioneered groundbreaking treatments for rare diseases, The Termeer Foundation connects life science innovators and catalyzes the creation of new medicines. The Foundation’s network of emerging and established healthcare innovators cultivates tomorrow’s leaders and leverages their collective expertise to solve complex problems in drug development and accessibility. The Foundation also integrates its network with academic institutions, nonprofits, regulatory agencies and other organizations across the global healthcare ecosystem to provide expert counsel, stimulate innovation, eliminate barriers to progress, and ultimately connect the world of healthcare until every patient has a cure.

Visit us at www.termeerfoundation.org or on LinkedIn @TermeerFoundation.

Contacts
Erica Mawby-Roche
Termeer Foundation
erica@termeerfoundation.org

Seed Round Funding Press Release

Dutch biotech Xinvento raises seed round to develop a treatment for the rare disease Congenital Hyperinsulinism

Amsterdam, the Netherlands, 21 April 2022 – Xinvento, a biotech company aiming to improve the lives of those with Congenital Hyperinsulinism, announces today the completion of a seed funding round.

The company is financially backed and advised by drug development experts and seasoned biotech leaders such as Ed Kaye (CEO Stoke Therapeutics), John Maraganore (former CEO Alnylam), David Meeker (CEO Rhythm Pharmaceuticals, former CEO Sanofi Genzyme), Hans Schikan (former CEO Prosensa and co-founder Pharvaris), James Shannon (former CMO GSK and Global Head of Development Novartis), Onno van de Stolpe (founder and former CEO Galapagos), Daniel de Boer (founder and CEO ProQR) and Dinko Valerio (co-founder Leyden Labs, founder Crucell).

Xinvento was founded in 2021 by CEO Claudine van der Sande, the driving force behind the company, who has a son diagnosed with Congenital Hyperinsulinism (CHI). This rare disease is characterized by hypoglycemia (hypos) resulting from an over-secretion of insulin. CHI is the most frequent cause of severe, random, and persistent hypos in newborns and children. Without proper and immediate treatment to prevent hypos, the patient may suffer seizures, coma, permanent brain damage, or even death. There currently are limited effective treatment options available to CHI patients.

“With my background in the pharmaceutical industry and facing the lack of real treatment options for children like mine with CHI, I saw an opportunity to make a difference. With seed funding secured, the first steps towards an effective and safe treatment are becoming a reality,”

said Claudine van der Sande, founding CEO of Xinvento.

This seed funding will enable Xinvento to design and test its proprietary molecules in the relevant pre-clinical models to identify potential drug candidates. Piet Wigerinck, a translational chemistry expert, former CSO of Galapagos, and the scientific co-founder leading the Xinvento R&D efforts, comments:

“I’m passionate to contribute to the search for a new drug that effectively controls the secretion of insulin, which will be a major step forward in the treatment of CHI. The science behind the Xinvento program is intriguing, as it can benefit to a great extent from all the knowledge and experience gathered over the past 20 years. This has enabled us to select a promising target and with a focused research program, we expect to deliver clinical candidate molecules within one year.”

Dinko Valerio, founding advisor, commented:

“In founding Xinvento, Claudine successfully surrounded herself with top-class veterans from our industry, including Piet Wigerinck, who saw a near-term opportunity to develop a meaningful drug for CHI patients in need. Claudine stands out as a focused leader who will leave no stone unturned to achieve Xinvento’s goal.”

About Xinvento

Xinvento aims to alleviate the difficulties associated with Congenital Hyperinsulinism (CHI). By developing an effective treatment our focus is to improve the quality of life of CHI patients and their families.

Inspired by Love, Powered by Science.

Contact

Claudine van der Sande Founding CEO

info@xinvento.com